Compare SFBS & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBS | TVTX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2014 | 2013 |
| Metric | SFBS | TVTX |
|---|---|---|
| Price | $73.96 | $27.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $87.50 | $36.25 |
| AVG Volume (30 Days) | 342.4K | ★ 1.0M |
| Earning Date | 04-20-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | 21.63 | ★ 92.89 |
| EPS | ★ 5.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.30 | $44.62 |
| Revenue Next Year | $10.30 | $31.76 |
| P/E Ratio | $14.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $66.48 | $12.91 |
| 52 Week High | $90.64 | $42.13 |
| Indicator | SFBS | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 45.44 |
| Support Level | $71.28 | $26.72 |
| Resistance Level | $76.88 | $31.47 |
| Average True Range (ATR) | 2.26 | 1.09 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 51.48 | 42.49 |
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.